IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma

Introduction: Therapeutic options for mycosis fungoides and Sézary syndrome include a variety of immunomodulatory, epigenetic, and cytotoxic options; however, none has been demonstrated to be efficacious for all patients, or to deliver deep and durable responses to the majority of patients. In this review, we examine the monoclonal antibody, IPH4102, a novel agent for the treatment of cutaneous T-cell lymphoma.

Areas covered: In this review, we examine data demonstrating the tissue specificity of KIR3DL2 receptor, which is highly expressed on the malignant cells in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome. This specificity has led to the development of the agent IPH4102. Preclinical data showing efficacy of IPH4102 in vivo are outlined, as well as the results from Phase I clinical trials, which suggest that the agent is both efficacious and well-tolerated. Larger scale clinical trials are to follow.

Expert Opinion: We examine the putative benefit of IPH4102 in comparison to established agents already in the clinic, highlighting its efficacy and relative safety. We also examine possible directions that may better define the role of IPH4102 in the treatment of T-cell lymphoma in the future.     

Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings,National Institute of Allergy and Infectious Diseases,Bethesda, Maryland,USA, May 21, 2015

On May 21st, 2015, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on delivery devices for nucleic acid (NA) as vaccines in order to review the landscape of past and future technologies for administering NA (e.g., DNA, RNA, etc.) as antigen into target tissues of animal models and humans. Its focus was on current and future applications for preventing and treating human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) disease, among other infectious-disease priorities. Meeting participants presented the results and experience of representative clinical trials of NA vaccines using a variety of alternative delivery devices, as well as a broader group of methods studied in animal models and at bench top, to improve upon the performance and/or avoid the drawbacks of conventional needle-syringe (N–S) delivery. The subjects described and discussed included (1) delivery targeted into oral, cutaneous/intradermal, nasal, upper and lower respiratory, and intramuscular tissues; (2) devices and techniques for jet injection, solid, hollow, and dissolving microneedles, patches for topical passive diffusion or iontophoresis, electroporation, thermal microporation, nasal sprayers, aerosol upper-respiratory and pulmonary inhalation, stratum-corneum ablation by ultrasound, chemicals, and mechanical abrasion, and kinetic/ballistic delivery; (3) antigens, adjuvants, and carriers such as DNA, messenger RNA, synthesized plasmids, chemokines, wet and dry aerosols, and pollen-grain and microparticle vectors; and (4) the clinical experience and humoral, cellular, and cytokine immune responses observed for many of these target tissues, technologies, constructs, and carriers. This report summarizes the presentations and discussions from the workshop (https://web.archive.org/web/20160228112310/https://www.blsmeetings.net/NucleicAcidDeliveryDevices/), which was webcast live in its entirety and archived online (http://videocast.nih.gov/summary.asp?live=16059).     

带足背皮神经的第1跖背动脉皮瓣修复食指皮肤缺损

目的：探讨带足背内侧皮神经的第1跖背动脉皮瓣修复食指皮肤缺损的临床应用及疗效。方法2002年3月-2012年5月,采用第1跖背动脉皮瓣游离移植修复食指皮肤缺损25例。结果25例获随访6～48个月,平均24个月。术后22例伤口一期愈合,皮瓣及植皮完全成活,食指屈伸功能正常,完全恢复正常生活及工作;2例皮瓣基本成活,远端部分坏死,足背供区植皮部分坏死,经清创换药后二期愈合,食指屈伸功能轻度受限,较好地恢复生活及工作;1例皮瓣完全坏死,改为同侧带蒂腹股沟皮瓣修复后治愈,足背供区植皮成活,食指屈伸功能明显受限。结论第1跖背动脉皮瓣游离移植是修复食指皮肤缺损的理想术式,该皮瓣解剖位置恒定,操作较可靠,成活率较高,外观、功能恢复优良,效果满意。     

595nm脉冲染料激光治疗皮肤血管性疾病的疗效

目的 探讨595 nm脉冲染料激光（pulsed dye laser,PDL）治疗皮肤血管性疾病的疗效和不良反应,并分析与疗效相关的因素.方法 采用595 nm PDL治疗血管瘤、鲜红斑痣、毛细血管扩张、酒糟鼻、蜘蛛痣等各类皮肤血管性疾病572例,对比不同病变的治疗效果及不良反应,分析疗效与患者性别、年龄、病变类型、病灶部位等因素的相关性.结果 治疗疗效与患者年龄、疾病性质、部位等因素相关（P＜0.05）,与性别无明显相关性;治疗后不良反应率为2.27％.结论 595 nmPDL治疗皮肤血管性疾病安全性高,疗效良好,不良反应低,是目前较为理想的治疗方法.     

Exoproteome analysis of a novel strain of Bacillus cereus implicated in disease resembling cutaneous anthrax

Bacillus cereus belongs to B. cereus sensu lato group, shared by six other related species including Bacillus anthracis. B. anthracis is the causative agent for serious illness affecting a wide range of animals as well as humans and is a category A Biological and Toxin Warfare (BTW) agent. Recent studies indicate that a Bacillus species other than B. anthracis can cause anthrax-like disease and role of anthrax virulence plasmids (pXO1 and pXO2) on the pathogenicity of B. cereus has been documented. B. cereus strain TF5 was isolated from the tissue fluid of cutaneous anthrax-like skin lesions of a human patient from an anthrax endemic area in India. The strain harboured a PA gene, however, presence of pXO1 or pXO2-like plasmids could not be ascertained using reported primers. Abundant exoproteome of the strain in the early stationary phase was elucidated using a 2-DE MS approach and compared with that from a reference B. cereus strain. Analysis of proteins showing qualitative and quantitative differences between the two strains indicated an altered regulatory mechanism and putative role of S-layer protein and sphingomyelinase in the pathogenesis of strain TF5. Phylogenetic analysis of the S-layer protein indicated close affiliation of the strain with anthracis-like B. cereus strains such as B. cereus var. anthracis strain CI; whereas sphingomyelinase exhibited specific relationship with all the strains of B. anthracis apart from that with anthracis-like B. cereus strains.